FDA grants priority review for mobocertinib for egfr exon20 insertion+ metastatic non-small cell lung cancer
The market authorisation application for this first-in-class, oral tyrosine kinase inhibitor specifically designed to selectively target epidermal growth factor receptor Exon20 insertion mutations was primarily based on results from a Phase 1/2 trial.
Source:
Biospace Inc.